SHO-SAIKO-TO for Patients With Chronic Hepatitis C: A Phase II Study
NCT00590564
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
42
Enrollment
OTHER
Sponsor class
Conditions
Hepatitis C
Interventions
DRUG:
Sho-saiko-to
Sponsor
Memorial Sloan Kettering Cancer Center